Brello Health review

Brello publishes exact NAD⁺ and sermorelin charges and maps 40 states plus DC. Budget for $297 or $349 upfront and every 11 weeks, not the seller’s $99/$116 monthly headlines. Its terms name Southend Pharmacy and its consent names Telegra MD; assigned clinicians, prescribed supply and several refund-policy conflicts still need confirmation.

Brello Health is a telehealth platform marketed around longevity care for women, with compounded GLP-1 products and sermorelin, NAD⁺, glutathione, MICC and bundles. The terms identify Brello, LLC as platform and AP Max, Inc. d/b/a Southend Pharmacy for fulfillment; telehealth consent names Telegra MD, LLC. These disclosures do not independently verify credentials or an individual assignment. Plans advertise medication if approved, a health review, injection supplies/instructions, app tracking, fitness/nutrition classes, community and support. Its map lists 40 states plus DC, excluding California, Michigan, Indiana, Arkansas, Alabama, North Carolina, South Carolina, Massachusetts, Connecticut and New Jersey. The site displays a LegitScript seal.

Payment comes before online intake and provider review. Approved orders are described as shipping within 3–5 business days, rather than guaranteeing arrival then. Consent allows audio, video and data communication; provider and customer support are advertised, with no exact ongoing visit frequency established. Terms require 18+ and physical presence in a served U.S. state; consent describes out-of-pocket care without insurance. The seller calls these three-month plans with a three-month minimum, yet specifies automatic renewal every 11 weeks. Neither label establishes individualized medication supply. No required baseline lab charge is established. Confirm assigned clinician, pharmacy and any additional fees; terms permit requesting a separate pharmacy with separate medication payment.

NAD⁺ costs $297 upfront and $297 every 11 weeks until canceled. Sermorelin costs $349 upfront and $349 every 11 weeks, with a $599 reference total. Brello separately advertises $99/month NAD⁺ against $117 and $116/month sermorelin against $199. Those are seller headlines, not calendar-month prices: the three-month labels and selector conflict with the exact 11-week renewal cadence. Do not infer a $348 sermorelin total or a guaranteed three-month supply; vial amount, concentration and prescribed duration are not established. Confirm taxes, shipping and any additional provider or lab fees.

The detailed refund policy allows a full refund before health review or after nonapproval without a prescription. After prescription issuance but before dispensing, cancellation email must arrive within 24 hours of the review-complete/prescription-issued notification email for a refund less $50. Dispensed medication is nonrefundable. The FAQ instead describes the clock from review completion, and terms call professional fees nonrefundable, so obtain the applicable cutoff and exceptions. Report shipment/dispensing concerns within 48 hours. The policy describes investigation of confirmed-delivery nonreceipt, with possible replacement reimbursement, while homepage/FAQ wording broadly denies reshipment. A future-renewal cancellation deadline is not established.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Brello describes a US-based 503A compounding pharmacy; terms identify AP Max, Inc. d/b/a Southend Pharmacy. Confirm your assigned dispenser. 503A facilities compound for individual patients and operate under different oversight from 503B outsourcing facilities. On the evidence, the longevity line splits several ways and the price list does not. Sermorelin acts on the growth-hormone axis, a real and well-described mechanism with thin long-term human outcome data and no controlled trial behind the recovery or body-composition claims. Injectable NAD⁺ has no controlled human outcome trials at all; the oral precursors NR and NMN are the studied forms, and what they demonstrate is a raised blood NAD⁺ level rather than a clinical benefit. Injectable glutathione and the MICC lipotropic injection have essentially no controlled human outcome evidence for the claims made about them. Bundling them into one discounted monthly figure makes them look like one product; they are different evidence stories. Individual results vary.